The Swiss Group for Clinical Cancer Research (SAKK) looks back on a successful fiscal year in its 2024 Annual Report. With 67 active clinical trials, 38 scientific publications, and new strategic partnerships, SAKK reaffirms its leading role in independent cancer research. Under the leadership of its new CEO, Vincent Gruntz, key processes were streamlined and digital solutions implemented. Financially, the organization reports a positive balance for the third consecutive year.

For more information.